Sarepta Therapeutics Fellowships

At Sarepta, our work extends beyond the research and development of medicines. We're also committed to engaging with and supporting the rare disease ...

Sarepta Therapeutics - Annual Clinical Genetics Meeting 2025

Sponsors · Inozyme Pharma · Baylor Genetics · Jnana Therapeutics · Ultragenyx · BioMarin · Amicus Therapeutics · Acadia Pharma · Rhthym Pharma.

Fellowship Alumni | Saint Joseph's University

Fellowship Alumni ; 2015 - 2019 Fellows. 2015 Fellows. Jameson A. Korb, PharmD. Senior Medical Science Liaison Sarepta Therapeutics ; 2011- 2014 Fellows. 2011 ...

Sarepta Therapeutics Inc. (Durham) | North Carolina Biotech Center

Sarepta Therapeutics develops precision genetic medicine treatments for Duchenne muscular dystrophy (DMD), Limb-girdle muscular dystrophy (LGMD) and other ...

Sarepta Therapeutics - YouTube

Sarepta Therapeutics · One Sarepta · Gene Therapy Education: Spanish subtitles · SareptAssist · Gene Therapy Education · Route 79, The Duchenne Scholarship Program.

DMD Treatment Options | Sarepta DMD for Healthcare Professionals

Sarepta Treatments for Duchenne Muscular Dystrophy. Driving Innovation With the Power of Science. Learn how Sarepta therapies may help your patients living ...

Sarepta Therapeutics Announces Recipients of the 6th Annual ...

Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year 9/7/2023.

Apply for Inaugural Fellowship to Explore the Intersection of Science ...

You'll apply your knowledge of cutting-edge science and the technology of gene and cell therapies to help create new policies, modernize ...

US FDA approves expanded use of Sarepta's Duchenne gene therapy

The U.S. Food and Drug Administration allowed the expanded use of Sarepta Therapeutics' gene therapy for patients with Duchenne muscular ...

Sarepta Therapeutics Jobs & Careers - 25 Open Positions | Glassdoor

Sarepta Therapeutics Jobs · Sr. Manager, Quantitative Clinical Pharmacology · Scientist I, Quality Control. Andover, MA · Sr. · HR Systems Analyst · Associate ...

Sarepta Therapeutics | Apply for Route 79 today! We're awarding up ...

Apply for Route 79 today! We're awarding up to 20 scholarships to individuals living with Duchenne and an additional 5 academic scholarships ...

Sarepta Therapeutics Jobs, Employment | Indeed.com

Sarepta therapeutics jobs · Scientist I, Quality Control · $96,000 - $120,000 · HR Systems Analyst · $88,000 - $110,000 · Associate Director, Patient Affairs.

Congratulations to the recipients of the 2024 Route 79 Scholarships ...

Photo by Sarepta Therapeutics on September 17, 2024. May be an image of 4.

SRPT Sarepta Therapeutics, Inc. Stock Price & Overview

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics.

Sarepta Therapeutics Profile: Summary - OpenSecrets

Sarepta Therapeutics organization profile. Contributions in the 2024 cycle: $157741. Lobbying in 2024: $730000. Outside Spending in the 2024 cycle: $0.

Sarepta announces gene therapy program for LGMD2A/R1

Sarepta Therapeutics, Inc. announced that it executed an exclusive license agreement for an LGMD2A/R1 gene therapy program developed by Dr. Zarife Sahenk.

Sarepta Therapeutics - Boston - SAPA-NE

paid internships for summer 2024 in greater Boston, MA, Columbus, OH, Durham, NC, and virtual/remote. Sarepta is a biotech serving the rare ...

Cambridge biotech Sarepta wins fast-track approval for the first ...

The Food and Drug Administration on Thursday approved the first gene therapy for Duchenne muscular dystrophy, a $3.2 million one-time treatment ...

Genetics & Public Policy Fellowship Alumni - ASHG

... Sarepta Therapeutics. Senior Director, Science and Regulatory Policy. Sen. Elizabeth Warren. 2012. Laura Koontz. Foundation Medicine. Senior Director of Public ...

About Us - Sarepta Therapeutics

We're collaborating with health networks and payers, rethinking pricing models for revolutionary new treatments in development. We are in a daily race to ...